Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

A lyophilized open-source RT-LAMP assay for molecular diagnostics in resource-limited settings

  • Matl, Martin
  • Kellner, Max J.
  • Ansah, Felix
  • Grishkovskaya, Irina
  • Handler, Dominik
  • Heinen, Robert
  • Bauer, Benedikt
  • Menéndez-Arias, Luis
  • Auer, Thomas O.
  • Prieto-Godino, Lucia L.
  • Penninger, Josef M.
  • Vienna Covid-19 Detection Initiative (VCDI)
  • Awandare, Gordon A.
  • Brennecke, Julius
  • Pauli, Andrea
A critical bottleneck for equitable access to population-scale molecular diagnostics is the limited availability of rapid, inexpensive point-of-care tests especially in low- and middle-income countries. Here, we developed an open-source Reverse transcription loop-mediated isothermal amplification (RT-LAMP) molecular assay for the detection of respiratory RNA virus infections. It is based on non-proprietary enzymes, namely HIV-1 reverse transcriptase, Bst LF DNA polymerase and UDG BMTU thermolabile uracil DNA glycosylase. Formulated as liquid or lyophilized reaction mixtures, these reagents enable sensitive colorimetric detection of respiratory samples without the need for prior nucleic acid isolation. We evaluated our open-source lyophilized RT-LAMP assay on clinical samples with suspected COVID-19 infection, demonstrating high sensitivity and 100% specificity compared to the gold standard Reverse transcription quantitative polymerase chain reaction (RT-qPCR). Reaction performance was unaffected by prolonged storage of lyophilized reagents at ambient or elevated temperatures. As a proof of concept, we evaluated the robustness and ease-of-use of lyophilized RT-LAMP reaction mixes through independent laboratory testing of COVID-19 samples in Ghana. Overall, our open-source RT-LAMP assay provides a flexible and scalable point-of-care test that can be adapted for rapid detection of various pathogens in resource-limited settings., M.M. and M.J.K. were supported by the Vienna Science and Technology Fund (WWTF) through project COV20-031. This project received funding from the VW foundation (grant # 9A027) given to TReND in Africa, as well as funding from the "Mila Charitable Organisation". The IMP receives generous institutional funding from Boehringer Ingelheim and the Austrian Research Promotion Agency (Headquarter grant FFG852936), and IMBA is generously supported by the Austrian Academy of Sciences. Research in the lab of A.P. was supported by the Austrian Science Fund (START Projekt Y 1031-B28, SFB “RNA-Deco” F 80). Research in the lab of J.B. was supported by the European Research Council (ERC2015-CoG - 682181). F.A and G.A.A. were supported by a Science for Africa Foundation (SFA)/Wellcome Developing Excellence in Leadership Training and Science (DELTAS) in Africa grant (DEL-22-014: Awandare, G). Work in the L.M.-A. laboratory was supported by grant PID2019104176RBI00/AEI/10.13039/501100011033 of the Spanish Ministry of Science and Innovation, and an institutional grant of the Fundación Ramón Areces. The laboratory of J.M.P. at IMBA received funding from the Austrian Academy of Sciences, the Medical University of Vienna, the Swedish Research Council (2018- 05766), the T. von Zastrow foundation, and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101005026. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA., No